万维提示：
1、该刊只有国际刊号！
2、投稿方式：在线投稿。
3、官网网址：
https://onlinelibrary.wiley.com/journal/26882663
（微信公众号信息）
4、投稿系统：https://mc.manuscriptcentral.com/medcomm
5、主办单位官网：https://www.scimea.cn/
（四川省国际医学交流促进会）
6、官网邮箱：
editorial@med-comm.org（编辑部）
review@med-comm.org（编辑部）
7、出刊日期：月刊，每月出版1期。
8、官方微信公众号：四川省国际医学交流促进会（scimea）
2025年3月10日星期一
MedComm简介
MedComm 是由中国科学院院士魏于全教授亲自操刀的又一优秀生物医学期刊。魏院士2016年创办的一流学术期刊Signal Transduction and Targeted Therapy（简称STTT），2020年影响因子18.187，位于SCI期刊JCR分区Q1区，全球生物化学和分子生物类期刊排名第5、细胞生物学类期刊排名第11。我们有理由相信MedComm 潜力无限，未来可期，成为高水平的国际期刊。
MedComm 是2020年由世界顶级出版集团Wiley出版的生物医学英文期刊（https://onlinelibrary.wiley.com/journal/26882663），目前已被ESCI、DOAJ、BIOSIS Previews等知名数据库收录，大部分论文PubMed也已收录。MedComm 竭诚欢迎生物医学领域的科研工作者、医生、研究生积极投稿。
MedComm 编委团队由英国牛津大学James Henderson Naismith教授（英国皇家科学院院士、英国皇家爱丁堡科学院院士）、耶鲁大学Günter P. Wagner教授（美国国家科学院院士、美国科学促进会院士、美国艺术与科学院院士）、川大华西医院生物治疗国家重点实验室魏于全教授（中国科学院院士）领导。编委团队由全球10多个国家的著名科学家构成，其中超过20%为国内外院士，60%以上为国外专家，包括宋伟宏院士、蒋华良院士、彭勇、黄灿华以及何明亮教授等著名专家教授。
创刊至今，MedComm 始终坚持高水平、国际化、严标准的办刊策略，所有刊载内容均经过严格的同行评审，专业高效的编辑团队管理，得到了国内外同行学者的广泛认可。MedComm 收到来自全球范围内顶尖大学和研究机构的高水平稿件。目前已在线发表80余篇论文，包括Biomaterials 主编Kam. W. Leong院士、英属哥伦比亚大学宋伟宏院士、南阿拉巴马大学Gary A. Piazza教授、多伦多大学Masoud Mozafari教授、哈佛医学院Wenjun Deng教授、美国圣约翰大学的陈哲生教授、天津医科大学姚智、第三军医大学叶丽林、浙江大学王福俤等国内外多位院士与教授的文章。MedComm 由衷地感谢期刊作者、审稿人、编辑和读者的巨大贡献, MedComm 将再接再厉，发表更多高质量的论文，更好地服务于全球的读者和作者。
《MedComm》投稿指南
【官网信息】
Author Guidelines
1. SUBMISSION
Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Free Format submission
MedComm now offers Free Format submission for a simplified and streamlined submission process.
Before you submit, you will need:
Your manuscript: this should be an editable file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract (which does need to be correctly styled), introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. If the figures are not of sufficiently high quality your manuscript may be delayed. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.
An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)
The title page of the manuscript, including:
Your co-author details, including affiliation and email address. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)
Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):
data availability statement
funding statement
conflict of interest disclosure
ethics approval statement
patient consent statement
permission to reproduce material from other sources
clinical trial registration
If you are invited to revise your manuscript after peer review, the journal will also request the revised manuscript to be formatted according to journal requirements, see details in Section 4. Preparing the Submission.
To submit, login at https://mc.manuscriptcentral.com/medcomm and create a new submission. Follow the submission steps as required and submit the manuscript.
Click here for more details on how to use ScholarOne.
Data protection:
By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
Preprint policy:
Please find the Wiley preprint policy here.
This journal accepts article previously published on preprint servers.
MedComm will consider for review articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.
For help with submissions, please contact: editorial@med-comm.org or review@med-comm.org
2. AIMS AND SCOPE
MedComm is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance on human health. The journal emphasizes on original findings that advances the understanding of pathogenesis or improves the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged.
MedComm is interested in the topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology or artificial intelligence. Clinical and experimental advances that provide the disease characteristics, pathogenic mechanism or medical techniques are focused by the journal.
Topics of interest include, but are not limited to:
Epigenetics, genomics, proteomics and metabonomics
Non-coding RNA in disease
Cell senescence and cell death
Cellular signal transduction
Gene therapy and Gene editing
Cancer immunology and Immunotherapy
Structural Biology, chemical genomics and drug discovery
High-definition imaging
Artificial intelligence in medicine
Stem cells and Regenerative medicine
Nanomedicine and drug delivery system
Early disease diagnosis and biomarkers
Clinical trials evaluating new treatments for cancer or other diseases
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/26882663/homepage/author-guidelines
